Beleaguered drugmaker Wockhardt has a new management team in place to implement a three-year strategic plan to get back on track. The company has seen at least four senior-level exits in the last few months.
The Reliance-Anil Dhirubhai Ambani Group has picked up a 15 per cent stake for Rs 225 crore (Rs 2.25 billion) in a new international airport coming up at Aranmula in Pathanamthitta district of central Kerala.
Major Indian drug companies such as Ranbaxy Laboratories, Lupin, Dr Reddy's Laboratories and Glenmark have gone off the beaten track in overseas markets.
Major drug discovery outsourcing deals have almost dried up in the past 18 months for almost all prominent players in the area
An increase in the number of outsourcing deals between domestic drug companies and pharmaceutical multinationals has triggered huge capacity expansion programmes in the drug manufacturing sector.
Indian pharmaceutical companies may have spread their wings far and wide, but they have been hitting the wall in China.
Three Indian companies are among the six shortlised to bid for the privatisation of the Male International Airport in Maldives.
Last week, scientists working with the Institute of Genomics and Integrative Biology (IGIB) in New Delhi decoded the genome of a 52-year-old man from Jharkhand after nine weeks of study -- a first in the country. The feat has helped India join a select club of countries -- the US, UK, Canada, Korea and China.
The share prices of power transmission and distribution company Areva T&D rose 2.8 per cent on the Bombay Stock Exchange on Tuesday in anticipation of a possible open offer. A combine of Alstom and Schneider Electric have bought the entire stake in it of its majority holder, French nuclear major Areva.
European wind turbine makers interested; deal could be $1 billion. The company aims to raise about $1 billion from the sale of a 61.28 per cent stake, said two banking sources.
India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing.
The central government's decision to continue controlling supply of the swine flu drug, oseltamivir, will help the drug innovator, Swiss multinational Hoffmann-La Roche, and its Indian licencee, Hetero Drugs, maintain their effective monopoly in the country, even as the drug lacks patent protection in India, fear domestic industry circles.
Bangalore-based Stempeutics Research received clearance from the Drug Controller General of India to conduct human clinical trials to develop drugs using stem cells. With this, India became the first country after the US to allow human clinical trials to develop drugs by using dormant cells in the body that have natural regeneration capabilities. Once injected into a patient, the stem cells can be controlled with a simple magnet to direct them to the damaged area and cure
In another development, leading Japanese drug maker Takeda Pharmaceutical sued Ahmedabad-based Torrent Pharma in the US for infringing seven patents covering its flagship diabetes drug, Actos. Oracea (doxycycline) is the only US Food and Drug Administration approved oral drug to treat rosacea -- a skin disorder in the face with inflammation, skin redness and spider veins.
Novartis's famed cancer drug, Glivec, will not get patent protection in India. The apex body on patent and trademark disputes, the Intellectual Property Appellate Board (IPAB), has ruled that the drug "lacks innovation" and the high price tag of Rs 120,000 per month per patient would be too high for the common man.
In what could be one of the largest outsourcing deals in the Indian telecom space, Reliance Communications is close to awarding a $500-600 million (Rs 2,500-3,000 crore) operations and maintenance contract to Foprench telecom infrastructure provider Alactel-Lucent.
The world's fifth largest wind turbine maker, Suzlon Energy, which has been grappling with quality issues with its rotor blades in the US and struggling to repay debt, finds itself in rough weather yet again -- this time in its home turf near Pune.
The company is likely to increase buy-back offer from Rs 351 to Rs 425-450. The open offer price is likely to be revised from the earlier Rs 351 to between Rs 425 and Rs 450, as the current share prices of Novartis India are above the present open offer price, the sources added.
GSK India, which has a turnover of Rs 1,751 crore (Rs 17.51 billion) and launched a cervical cancer drug, Cervarix, and breast cancer drug, Tykerb, last year, plans to launch Promacta, the first oral medication to increase platelet production for people with serious blood disorder, from its parent stable during the current year. Promacta is a relatively new drug, for which approval was given by the US Food and Drug Administration in November last year.
Mukesh Ambani's privately held biotech research company, Reliance Life Sciences, will soon diversify to take up biofuel production in a major way. Industry sources said the facilities might require an investment of Rs 150-200 crore (Rs 1.5 billion to Rs 2 billion). One hectare of land yields about a tonne of crop, so RLS will need to cultivate about one lakh hectares of land, they say. The majority of investments go into sourcing raw material, they say.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances